Santiago Parpal

Santiago Parpal

Auto-generated profile, based on publicly available information

Santiago Parpal

Sprint Bioscience, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 1999 in The FASEB Journal
Verified
Journal Article
Closed access
JGJohanna Gustavsson
Johanna Gustavsson
SPSantiago Parpal
Santiago Parpal
MKMargareta Karlsson
Margareta Karlsson
CRCecilia Ramsing
Cecilia Ramsing
HTHans Thorn
Hans Thorn
PSPeter Strålfors
Peter Strålfors

1 March 2001 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
SPSantiago Parpal
Santiago Parpal
MKMargareta Karlsson
Margareta Karlsson
HTHans Thorn
Hans Thorn
PSPeter Strålfors
Peter Strålfors
Insulin exerts its cellular control through receptor binding in caveolae in plasmalemma of target cells (Gustavsson, J., Parpal, S., Karlsson, M., Ramsing, C., Thorn, H., Borg, M., Lindroth, M., Peterson, K. H., Magnusson, K.-E., and Strålfors, P. (1999) FASEB. J. 13, 1961–1971). We now report that a progressive cholesterol depletion of 3T3-L1 adipocytes with β-cyclodextrin gradually destroyed caveolae structures and concomitantly attenuated insulin stimulation of glucose transport, in effect making cells insulin-resistant. Insulin access to or affinity for the insulin receptor on rat adipocytes was not affected as determined by 125I-insulin binding. By immunoblotting of plasma membranes, total amount of insulin receptor and of caveolin remained unchanged. Receptor autophosphorylation in response to insulin was not affected by cholesterol depletion. Insulin treatment of isolated caveolae preparations increased autophosphorylation of receptor before and following cholesterol depletion. Insulin-increased tyrosine phosphorylation of an immediate downstream signal transducer, insulin receptor substrate-1, and activation of the further downstream protein kinase B were inhibited. In contrast, insulin signaling to mitogenic control as determined by control of the extracellular signal-related kinases 1/2, mitogen-activated protein kinase pathway was not affected. Insulin did not control Shc phosphorylation, and Shc did not control extracellular signal-related kinases 1/2, whereas cholesterol depletion constitutively phosphorylated Shc. In conclusion, caveolae are critical for propagating the insulin receptor signal to downstream targets and have the potential for sorting signal transduction for metabolic and mitogenic effects.

1 May 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
MNMuhmmad Zaeem Noman
Muhmmad Zaeem Noman
SPSantiago Parpal
Santiago Parpal
KMKris Van Moer
Kris Van Moer
MXMalina Xiao
Malina Xiao
YYYasmin Yu
Yasmin Yu
Bassam JanjiBassam Janji
Bassam Janji
One of the major challenges limiting the efficacy of anti–PD-1/PD-L1 therapy in nonresponding patients is the failure of T cells to penetrate the tumor microenvironment. We showed that genetic or pharmacological inhibition of Vps34 kinase activity using SB02024 or SAR405 (Vps34i) decreased the tumor growth and improved mice survival in multiple tumor models by inducing an infiltration of NK, CD8+, and CD4+ T effector cells in melanoma and CRC tumors. Such infiltration resulted in the establishment of a T cell−inflamed tumor microenvironment, characterized by the up-regulation of pro-inflammatory chemokines and cytokines, CCL5, CXCL10, and IFNγ. Vps34i treatment induced STAT1 and IRF7, involved in the up-regulation of CCL5 and CXCL10. Combining Vps34i improved the therapeutic benefit of anti–PD-L1/PD-1 in melanoma and CRC and prolonged mice survival. Our study revealed that targeting Vps34 turns cold into hot inflamed tumors, thus enhancing the efficacy of anti–PD-L1/PD-1 blockade.

1 October 2018 in Cancer Letters
Verified
Journal Article
Open access
MDMatheus Dyczynski
Matheus Dyczynski
YYYasmin Yu
Yasmin Yu
MOMagdalena Otrocka
Magdalena Otrocka
SPSantiago Parpal
Santiago Parpal
TBTiago Braga
Tiago Braga
KTKatja Pokrovskaja Tamm
Katja Pokrovskaja Tamm
Resistance to chemotherapy is a challenging problem for treatment of cancer patients and autophagy has been shown to mediate development of resistance. In this study we systematically screened a library of 306 known anti-cancer drugs for their ability to induce autophagy using a cell-based assay. 114 of the drugs were classified as autophagy inducers; for 16 drugs, the cytotoxicity was potentiated by siRNA-mediated knock-down of Atg7 and Vps34. These drugs were further evaluated in breast cancer cell lines for autophagy induction, and two tyrosine kinase inhibitors, Sunitinib and Erlotinib, were selected for further studies. For the pharmacological inhibition of autophagy, we have characterized here a novel highly potent selective inhibitor of Vps34, SB02024. SB02024 blocked autophagy in vitro and reduced xenograft growth of two breast cancer cell lines, MDA-MB-231 and MCF-7, in vivo. Vps34 inhibitor significantly potentiated cytotoxicity of Sunitinib and Erlotinib in MCF-7 and MDA-MB-231 in vitro in monolayer cultures and when grown as multicellular spheroids. Our data suggests that inhibition of autophagy significantly improves sensitivity to Sunitinib and Erlotinib and that Vps34 is a promising therapeutic target for combination strategies in breast cancer.

14 December 2001 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
MKMargareta Karlsson
Margareta Karlsson
HTHans Thorn
Hans Thorn
SPSantiago Parpal
Santiago Parpal
PSPeter Strålfors
Peter Strålfors
JGJohanna Gustavsson
Johanna Gustavsson
Insulin‐stimulated glucose uptake in muscle and adipose tissue is the result of translocation of insulin‐regulated glucose transporters (GLUT4) from intracellular vesicles to the plasma membrane. Here we report that GLUT4 in the plasma membrane of 3T3‐L1 adipocytes were located predominantly in caveolae invaginations: by immunogold electron microscopy of plasma membranes, 88% of GLUT4 were localized to caveolae structures and this distribution within the plasma membrane was not affected by insulin. By immunofluorescence microscopy, a major part of GLUT 4 was colocalized with caveolin. The total amount of GLUT4 in the plasma membrane increased 2.2‐fold in response to insulin as determined by immunogold electron or immunofluorescence microscopy. GLUT4 were enriched in caveolae fractions isolated without detergents from plasma membranes of rat adipocytes. In these fractions, GLUT4 were largely confined to caveolin‐containing membranes of the caveolae preparation isolated from insulin‐stimulated cells, determined by electron microscopy. Insulin increased the amount of GLUT4 2.7‐fold in this caveolae fraction. Caveolae were purified further by immunoisolation with antibodies against caveolin. The amount of GLUT4 increased to the same extent in the immunopurified caveolae as in the cruder caveolae fractions from insulin‐stimulated cells. We conclude that insulin induces translocation of GLUT4 to caveolae.

1 April 2012 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
TBTomas Borgegard
Tomas Borgegard
AJAnders Juréus
Anders Juréus
FOFredrik Olsson
Fredrik Olsson
SRSusanne Rosqvist
Susanne Rosqvist
ASAlan Sabirsh
Alan Sabirsh
JLJohan Lundkvist
Johan Lundkvist
γ-Secretase-mediated cleavage of amyloid precursor protein (APP) results in the production of Alzheimer disease-related amyloid-β (Aβ) peptides. The Aβ42 peptide in particular plays a pivotal role in Alzheimer disease pathogenesis and represents a major drug target. Several γ-secretase modulators (GSMs), such as the nonsteroidal anti-inflammatory drugs (R)-flurbiprofen and sulindac sulfide, have been suggested to modulate the Alzheimer-related Aβ production by targeting the APP. Here, we describe novel GSMs that are selective for Aβ modulation and do not impair processing of Notch, EphB2, or EphA4. The GSMs modulate Aβ both in cell and cell-free systems as well as lower amyloidogenic Aβ42 levels in the mouse brain. Both radioligand binding and cellular cross-competition experiments reveal a competitive relationship between the AstraZeneca (AZ) GSMs and the established second generation GSM, E2012, but a noncompetitive interaction between AZ GSMs and the first generation GSMs (R)-flurbiprofen and sulindac sulfide. The binding of a 3H-labeled AZ GSM analog does not co-localize with APP but overlaps anatomically with a γ-secretase targeting inhibitor in rodent brains. Combined, these data provide compelling evidence of a growing class of in vivo active GSMs, which are selective for Aβ modulation and have a different mechanism of action compared with the original class of GSMs described.